Targeted in vivo delivery of EGFR siRNA inhibits ovarian cancer growth and enhances drug sensitivity

Sci Rep. 2016 Nov 7:6:36518. doi: 10.1038/srep36518.

Abstract

A functionalized nanohydrogel siRNA delivery system and a mouse model of serous ovarian cancer were used to test predictions from previous cell line studies that knockdown of EGFR (epidermal growth factor receptor) may be of clinical significance in the treatment of epithelial tumors especially with respect to the enhancement of platinum based therapies. Our results support these predictions and suggest that targeted delivery of EGFR siRNA may be an effective strategy for the treatment of ovarian and other epithelial tumors associated with elevated levels of EGFR and especially those demonstrating resistance to platinum-based therapies.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects*
  • ErbB Receptors / genetics*
  • Female
  • Humans
  • Mice
  • Mice, SCID
  • Organoplatinum Compounds / pharmacology
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / genetics
  • RNA Interference / drug effects
  • RNA, Small Interfering / genetics

Substances

  • Antineoplastic Agents
  • Organoplatinum Compounds
  • RNA, Small Interfering
  • EGFR protein, mouse
  • ErbB Receptors